2023
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
Luukkonen P, Sakuma I, Gaspar R, Mooring M, Nasiri A, Kahn M, Zhang X, Zhang D, Sammalkorpi H, Penttilä A, Orho-Melander M, Arola J, Juuti A, Zhang X, Yimlamai D, Yki-Järvinen H, Petersen K, Shulman G. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2217543120. PMID: 36669104, PMCID: PMC9942818, DOI: 10.1073/pnas.2217543120.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fibrosisLiver diseaseCommon chronic liver diseaseChronic liver diseaseFatty liver diseaseRisk of fibrosisDistinct mouse modelsPyrimidine catabolismNonalcoholic steatohepatitisMouse modelTherapeutic targetFibrosisDihydropyrimidine dehydrogenaseHuman liverA variantCommon variantsMetabolomics approachDiseaseMiceInhibitionCatabolismKnockdownSteatohepatitisGimeracil
2016
Lymphocytic esophagitis: a histologic pattern with emerging clinical ramifications
Lisovsky M, Westerhoff M, Zhang X. Lymphocytic esophagitis: a histologic pattern with emerging clinical ramifications. Annals Of The New York Academy Of Sciences 2016, 1381: 133-138. PMID: 27635640, DOI: 10.1111/nyas.13260.Peer-Reviewed Original ResearchConceptsIntraepithelial lymphocytesCrohn's diseaseCommon clinical manifestationsNormal endoscopic appearanceLymphocytic esophagitisSignificant granulocytosisEndoscopic appearanceEosinophilic esophagitisMotility abnormalitiesMotility disordersClinical manifestationsHistologic patternClinical correlatesClinical significanceAssociated diseasePossible associationClinical ramificationsDiseaseEsophagitisAdultsAssociationDysphagiaCD4GranulocytosisEsophagus
2015
Interval colorectal carcinoma: An unsolved debate
Benedict M, Galvao Neto A, Zhang X. Interval colorectal carcinoma: An unsolved debate. World Journal Of Gastroenterology 2015, 21: 12735-12741. PMID: 26668498, PMCID: PMC4671029, DOI: 10.3748/wjg.v21.i45.12735.Peer-Reviewed Original ResearchConceptsInterval colorectal carcinomasColorectal carcinomaNegative screening testNew cancer diagnosesHigh-risk individualsPolypoid neoplasiasExcised lesionsGastrointestinal neoplasiaCommunity hospitalRisk individualsSignificant health riskScreening testMultifactorial natureCancer diagnosisNeoplasiaHealth risksUnsolved debatePatientsCarcinomaHospitalLesionsEndoscopistsDiseaseDiagnosis
2014
Pathology of Alcoholic Liver Disease
Celli R, Zhang X. Pathology of Alcoholic Liver Disease. Journal Of Clinical And Translational Hepatology 2014, 2: 103-109. PMID: 26357621, PMCID: PMC4521259, DOI: 10.14218/jcth.2014.00010.Peer-Reviewed Original ResearchAlcoholic liver diseaseLiver diseaseAlcohol consumptionLiver-related deathAlcohol-attributable burdenImportant differential diagnosisSeverity of diseaseLiver biopsyPathologic featuresPathologic manifestationsDifferential diagnosisPopulation alcohol consumptionDiseaseGlobal healthClinical workBiopsyPatientsPathophysiologyCliniciansDiagnosisLiverPathologySeverity
2013
Histopathologic Manifestations of Drug-induced Hepatotoxicity
Zhang X, Ouyang J, Thung SN. Histopathologic Manifestations of Drug-induced Hepatotoxicity. Clinics In Liver Disease 2013, 17: 547-564. PMID: 24099017, DOI: 10.1016/j.cld.2013.07.004.Peer-Reviewed Original ResearchConceptsDrug-induced hepatotoxicityChronic liver diseaseLiver diseaseCareful medication historySpecific histopathologic patternAbnormal liver testsLiver testsResponsible drugSymptom onsetLiver injuryMedication historyCounter medicationsHistopathologic patternHistopathologic findingsDrug exposureHistopathologic manifestationsHepatobiliary diseaseCertain drugsSupplementary agentPrescription drugsHepatotoxicityHerbal productsLatent periodDiseaseDrugs